The Efficacy of Tongue Stabilizing Device in Patients With Obstructive Sleep Apnea
Primary Purpose
Obstructive Sleep Apnea
Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Tongue Stabilizing Device (TSD)
Sponsored by
About this trial
This is an interventional treatment trial for Obstructive Sleep Apnea
Eligibility Criteria
Inclusion Criteria
Patients included in this study must:
- be 18 years of age or older
- have an objective diagnosis of mild to moderate obstructive sleep apnea (OSA) [5 ≤ AHI ≤ 50]; and
- have a Body Mass Index (BMI) ≤ 35
Exclusion Criteria
Patients are excluded in this study who:
- have had previous surgery of the soft palate;
- have neuromuscular disease;
- are taking medications which disturb sleep; and/or
- have ≤ 90% oxygen saturation levels for 20% of the night.
Sites / Locations
- University of British Columbia
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Tongue Stabilizing Device Treatment
Arm Description
Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
Outcomes
Primary Outcome Measures
Apnea-hypopnea index
Measuring apnea-hypopnea index (events/hour) to measure intervention efficacy (e.g. AHI)
Apnea-hypopnea index
Measuring changes in apnea-hypopnea index (events/hour) to compare baseline and 2-6 months of TSD treatment follow up.
Frequency of swallowing
Measuring frequency of swallowing (events/hour) to assess influence by intervention
Frequency of swallowing
Measuring changes in frequency of swallowing (events/hour) to compare baseline and 2-6 months of TSD treatment follow up.
Secondary Outcome Measures
Functional Outcomes of Sleep Questionnaire (FOSQ) responses
Measuring Functional Outcomes of Sleep Questionnaire (FOSQ) responses to evaluate disease specific quality of life.
Functional Outcomes of Sleep Questionnaire (FOSQ) responses
Measuring changes in Functional Outcomes of Sleep Questionnaire (FOSQ) responses to compare baseline and 2-6 months of TSD treatment follow up
Epworth Sleepiness Scale (ESS) questionnaire responses.
Measuring responses to Epworth Sleepiness Scale (ESS) Questionnaire to assess daytime sleepiness.
Epworth Sleepiness Scale (ESS) questionnaire responses.
Measuring changes in responses to Epworth Sleepiness Scale (ESS) Questionnaire to compare baseline and 2-6 months of TSD treatment follow up
VR-36 survey responses
Measuring VR-36 survey responses which assesses general health status.
VR-36 survey responses
Measuring changes in VR-36 survey responses to compare baseline and 2-6 months of TSD treatment follow up
Breathing route
Measuring breathing route to assess influence by intervention
Breathing route
Measuring changes in breathing route to compare baseline and 2-6 months of TSD treatment follow up
Swallowing apnea time
Measuring swallowing apnea time (sec) to assess influence by intervention
Swallowing apnea time
Measuring changes in swallowing apnea time (sec) to compare baseline and 2-6 months of TSD treatment follow up
Compliance (Measuring adherence (hours/nights and nights/week of intervention use))
Measuring adherence (hours/nights and nights/week of intervention use)
Full Information
NCT ID
NCT02329925
First Posted
December 12, 2014
Last Updated
November 24, 2022
Sponsor
University of British Columbia
1. Study Identification
Unique Protocol Identification Number
NCT02329925
Brief Title
The Efficacy of Tongue Stabilizing Device in Patients With Obstructive Sleep Apnea
Official Title
The Efficacy of Tongue Stabilizing Device in Patients With Obstructive Sleep Apnea
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Completed
Study Start Date
January 2015 (Actual)
Primary Completion Date
May 2019 (Actual)
Study Completion Date
May 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of British Columbia
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The coordination of swallowing and breathing is an important mechanism because the route for air and deglutition is partly shared in the pharynx. Tongue Stabilizing Device (TSD) is a preformed appliance for Obstructive Sleep Apnea (OSA) that protrudes the tongue and improves upper airway structure and function during sleep. Investigators will attempt to assess efficacy of TSD therapy on OSA and the physiological change of swallowing and breathing routes in OSA patients during sleep.
Detailed Description
Purpose:
The purpose of this study is to determine the efficacy of TSD and to assess if it alters swallowing frequency and breathing modes in OSA patients during sleep.
Hypothesis:
Investigators hypothesize that TSD therapy will improve OSA symptoms and will lead to effective nasal breathing which may decrease swallowing frequency in OSA patients during sleep.
Justification:
The coordination of swallowing and breathing is an important mechanism because the route for air and deglutition is partly shared in the pharynx. OSA occurs when there is complete or partial obstruction in the pharynx during sleep which results in an impact on both breathing and swallowing. Continuous Positive Airway Pressure (CPAP) and Oral Appliance (OA) therapy improve breathing in OSA patients, but these therapies have some disadvantages such as poor adherence and expensiveness. TSD is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep. TSD is simpler and more economical than other therapies and may bring similar benefits. In regards to swallowing, it has been reported that swallowing frequency during sleep increases with OSA severity and when preceded by oronasal breathing. However, it still remains to be determined if the treatment of OSA alters breathing modes and swallowing frequency in OSA patients during sleep. An evaluation of the efficacy of TSD therapy on OSA and the physiological change of swallowing and breathing route may be an important step in the sleep medical field so as to understand the mechanism(s) by which TSD therapy improves the clinical condition of OSA.
Objectives:
The objective of this study is to clarify the mechanism(s) by which TSD therapy improves the clinical condition of OSA in terms of regulation of swallowing and breathing modes in OSA patients during sleep.
Research Methods:
Investigators plan to collect data from a minimum of 60 patients who have been diagnosed with OSA .In addition to the regular sleep study electrodes and measurements, investigators will require four supplementary standard sleep channels that utilize standard sleep recording tools. Breathing modes (pure nasal, oral and oro-nasal) will be evaluated with a nasal pressure transducer, which is traditionally used for patients' evaluation (Braebon) and an additional standard oral flow thermistor sensor (1) (Braebon). The degree of mouth opening will be scored with a jaw sensor® (2). Swallowing will be scored based on a combination of measurements which include laryngeal movements as recorded over the thyroid cartilage with a standard piezoelectric sensor (Opti-Flex, Newlife Technologies, Midlothian, VA, USA) (3), and a sub-mental(SupraHyoid) EMG used for the muscle activity of swallowing (4). Standard polysomnography (PSG) data will be analyzed manually according to AASM criteria by sleep technologists. After regular scoring and sleep evaluation, data from results of the sleep study will be transferred to a CD and one of the authors, Kentaro Okuno, will perform further analysis outside of the laboratory. Using the completed data for sleep stages, apnea and hypopnea events, the swallowing events and breathing modes will be assessed visually and scored. Each epoch will then be evaluated for temporal relation between breathing modes and swallowing as well as for degree of mouth opening, apneas, hypopneas, and arousals. The efficacy endpoint is the change in AHI between baseline and TSD. The polysomnographic results will be subjected to paired Student's t-Tests to demonstrate and difference between baseline and TSD.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
41 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Tongue Stabilizing Device Treatment
Arm Type
Experimental
Arm Description
Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
Intervention Type
Device
Intervention Name(s)
Tongue Stabilizing Device (TSD)
Intervention Description
Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
Primary Outcome Measure Information:
Title
Apnea-hypopnea index
Description
Measuring apnea-hypopnea index (events/hour) to measure intervention efficacy (e.g. AHI)
Time Frame
At baseline
Title
Apnea-hypopnea index
Description
Measuring changes in apnea-hypopnea index (events/hour) to compare baseline and 2-6 months of TSD treatment follow up.
Time Frame
At 2-6 months of TSD treatment follow up
Title
Frequency of swallowing
Description
Measuring frequency of swallowing (events/hour) to assess influence by intervention
Time Frame
At baseline
Title
Frequency of swallowing
Description
Measuring changes in frequency of swallowing (events/hour) to compare baseline and 2-6 months of TSD treatment follow up.
Time Frame
At 2-6 months of TSD treatment follow up
Secondary Outcome Measure Information:
Title
Functional Outcomes of Sleep Questionnaire (FOSQ) responses
Description
Measuring Functional Outcomes of Sleep Questionnaire (FOSQ) responses to evaluate disease specific quality of life.
Time Frame
At baseline
Title
Functional Outcomes of Sleep Questionnaire (FOSQ) responses
Description
Measuring changes in Functional Outcomes of Sleep Questionnaire (FOSQ) responses to compare baseline and 2-6 months of TSD treatment follow up
Time Frame
At 2-6 months of TSD treatment follow up
Title
Epworth Sleepiness Scale (ESS) questionnaire responses.
Description
Measuring responses to Epworth Sleepiness Scale (ESS) Questionnaire to assess daytime sleepiness.
Time Frame
At baseline
Title
Epworth Sleepiness Scale (ESS) questionnaire responses.
Description
Measuring changes in responses to Epworth Sleepiness Scale (ESS) Questionnaire to compare baseline and 2-6 months of TSD treatment follow up
Time Frame
At 2-6 months of TSD treatment follow up
Title
VR-36 survey responses
Description
Measuring VR-36 survey responses which assesses general health status.
Time Frame
At baseline
Title
VR-36 survey responses
Description
Measuring changes in VR-36 survey responses to compare baseline and 2-6 months of TSD treatment follow up
Time Frame
At 2-6 months of TSD treatment follow up
Title
Breathing route
Description
Measuring breathing route to assess influence by intervention
Time Frame
At baseline
Title
Breathing route
Description
Measuring changes in breathing route to compare baseline and 2-6 months of TSD treatment follow up
Time Frame
At 2-6 months of TSD treatment follow up
Title
Swallowing apnea time
Description
Measuring swallowing apnea time (sec) to assess influence by intervention
Time Frame
At baseline
Title
Swallowing apnea time
Description
Measuring changes in swallowing apnea time (sec) to compare baseline and 2-6 months of TSD treatment follow up
Time Frame
At 2-6 months of TSD treatment follow up
Title
Compliance (Measuring adherence (hours/nights and nights/week of intervention use))
Description
Measuring adherence (hours/nights and nights/week of intervention use)
Time Frame
At 2-6 months of TSD treatment follow up
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
Patients included in this study must:
be 18 years of age or older
have an objective diagnosis of mild to moderate obstructive sleep apnea (OSA) [5 ≤ AHI ≤ 50]; and
have a Body Mass Index (BMI) ≤ 35
Exclusion Criteria
Patients are excluded in this study who:
have had previous surgery of the soft palate;
have neuromuscular disease;
are taking medications which disturb sleep; and/or
have ≤ 90% oxygen saturation levels for 20% of the night.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fernanda R Almeida, DDS, MSc, PhD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of British Columbia
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6T 1Z3
Country
Canada
12. IPD Sharing Statement
Citations:
PubMed Identifier
33745505
Citation
Alshhrani WM, Hamoda MM, Okuno K, Kohzuka Y, Fleetham JA, Ayas NT, Comey R, Almeida FR. The efficacy of a titrated tongue-stabilizing device on obstructive sleep apnea: a quasi-experimental study. J Clin Sleep Med. 2021 Aug 1;17(8):1607-1618. doi: 10.5664/jcsm.9260.
Results Reference
derived
Learn more about this trial
The Efficacy of Tongue Stabilizing Device in Patients With Obstructive Sleep Apnea
We'll reach out to this number within 24 hrs